Expert Panels are Setup Within Weeks

A Patient's Perspective

Jenny Bogle—Ovarian cancer patient London, England.

Translate

"I recommend using CANCER PANELS for any patient who has a very complex illness and faces important questions on the best next steps in their options and treatment."

John Hutchins—Founder
PinnacleCare, Private Health Advisory

 

 

 

 

 

 

 

CONTACT US TODAY IN
STRICTEST CONFIDENCE
Call: 703-919-9945 (USA)

Email: jmartell@cancerpanels.com

Management

jmartell1

Jim Martell President & CEO

Jim Martell is the President and CEO of CANCER PANELS. In 1985, he founded a merger and acquisition company, International Group, Inc., which became Champions Sports, Inc. and eventually, Champions Oncology, Inc.

Jim Martell served the company in various capacities as its Chairman, President and CEO. In 2004, after his close friend and tennis partner was diagnosed with a highly metastatic and rare cancer, he met Dr. David Sidransky while searching for leading oncology experts and out-of-the-box thinkers. Since then Jim Martell worked and collaborated closely with Dr. Sidransky in the development of personalized expert cancer panels for cancer patients.

In 2007, together with Dr. Sidransky he co-founded Champions Oncology, Inc. by changing the business direction of Champions Sports, Inc. to biotechnology and oncology. From 2007 to 2012, Jim Martell served as an officer, director, and then consultant with Champions Oncology, Inc. Prior to 1985, he was a partner in several consulting companies specializing in European-American joint ventures, venture capital financing, technology transfer, corporate finance and international business development. Jim Martell received his Bachelor’s Degree in Chemistry and a Master’s Degree in Geochemistry from George Washington University.

Consultants

david

David Sidransky, M.D. Panel Chairman

Dr. David Sidransky is a consultant to CANCER PANELS. He is considered to be one of the world's leading cancer experts and pioneer in the field of molecular diagnostics, targeted therapies and individualized patient treatments. Dr. Sidransky was profiled in TIME magazine as one of the top physicians and scientists in America and is one of the five most highly cited oncology researchers in clinical and medical journals in the world during the past decade.

He is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is Professor of Oncology, Otolaryngology, Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University & Hospital in Baltimore, Maryland. 

In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers in clinical and medical journals in the world, with over 550 peer-reviewed publications in the past decade. He has also contributed to more than 70 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. From 2007 to 2017 he was the Chairman of Champions Oncology,Inc., a company he co-founded with Jim Martell, and currently is their Lead Director.  Dr. Sidransky has served as Vice Chairman of the Board of Directors of ImClone Systems, Inc., a global biopharmaceutical company and was a Director, until its merger with Ely Lilly and Company. He currently is a Managing Partner of Israel Biotech Fund , and serves on the Boards of Directors, of Advaxis ImmunotherapiesAyala Pharmaceuticals,  Rosetta Genomics and Orgenesis. Dr. Sidransky is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. From 2005 to 2008, he was on the Board of Directors of the American Association for Cancer Research (AACR) and was the Chairperson of the first and second (September 2006 and 2007) AACR International Conferences on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment.

Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Award from the AACR. He is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. Dr. Sidransky received his bachelor’s degree from Brandeis University and his medical degree from the Baylor College of Medicine.

Dr. David Sidransky's Press and Information Links:

Samir_Khleif_photo

Samir N. Khleif, M.D.

Dr. Samir Khleif is a consultant to CANCER PANELS. For more than 27 years he has been a pioneer and one of the leading researchers and key opinion leaders in the field of immunotherapy focusing on two areas of research:

1) understanding the molecular mechanisms of the interaction between cancer and the immune system and translating this knowledge into novel immune therapy and vaccines against cancer and 2) development of novel immune combination strategies.

Currently, Dr. Khleif is a Biomedical Scholar and Professor of Oncology at Georgetown University, in Washington DC, where he leads the development of a new innovative and high impact immune-oncology program translating many of his discoveries into high-impact clinical trials.

From 2012 to 2016 he was the Director of the Georgia Cancer Center of the Medical College of Georgia where he established a comprehensive Immuno-Oncology Program which connected basic research discovery to clinical trials with highly integrated translational elements. Previously, Dr. Khleif served as Chief of the Cancer Vaccine Section at National Cancer Institute (NCI), Professor of Medicine at Uniformed Services University of the Health Sciences and as a Special Assistant to the Food and Drug Administration Commissioner from 2006-2009, during which time he led the Critical Path Initiative for Oncology. During his tenure at the NCI, Dr. Khleif was detailed by the US government to develop and lead the King Hussein Cancer Centre in Jordan and served as its director from 2002-2006. He also served as Director of the King Hussein Cancer and Biotechnology Institute from 2006-2009. Dr. Khleif led many national efforts and committees on the development of bio-markers and integration of bio-markers in clinical trials, including the AACR-NCI-FDA Cancer Bio-marker Collaborative and the ASCO Alternative Clinical Trial Design. He is the author of many books, chapters, , and scientific articles on tumor immunology and bio-markers process development, and he is the editor for two textbooks on cancer therapeutics, tumor immunology and cancer vaccines. Dr. Khleif serves on many national and international committees driving the immune-oncology field and is a scientific advisor for more than 15 immuno-oncology companies. Furthermore, he also currently leads an international program to develop cancer care programs in low income countries. Dr. Khleif is the recipient of many national and international awards including the NCI’s Director Golden Star, the NIH Award for Merit, Georgia Distinguished Cancer Scientist and Clinician. He was appointed to the Institute of Medicine National Cancer Policy Forum and was inducted into the American Society for Clinical Investigation. Dr. Khleif received his medical degree from the University of Jordan in Amman, Jordan. He completed his fellowship in Medical Oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Samir Khleif's Press and Information Links: